Neil Gregory Almstead, who serves as Chief Technical Operations Officer at PTC Therapeutics (NASDAQ:PTCT), executed a series of stock sales on April 1, 2026 that totaled 51,953 shares of the company’s common stock. The disposals were carried out under a pre-arranged 10b5-1 trading plan and produced gross proceeds of $3.59 million.
The sales were completed across multiple transactions with trade prices spanning $68.89 to $70.30 per share. One tranche comprised 39,393 shares at a weighted average price of $68.89, with individual trade prices recorded between $68.26 and $69.26. A second tranche consisted of 12,530 shares at a weighted average price of $69.50, with prices ranging from $69.26 to $70.13. The final recorded sale was for 80 shares at $70.30.
Following these transactions, Almstead’s direct holdings in PTC Therapeutics stand at 60,137 shares. His spouse holds an additional 2,737 shares. PTC Therapeutics is currently valued at $5.61 billion and is assigned an "EXCELLENT" financial health score by InvestingPro, which also provides an extended Pro Research Report among more than 1,400 available for U.S. equities.
The sales occur against a backdrop of notable share-price appreciation and differing analyst views. PTC’s stock has climbed roughly 45% over the past year. InvestingPro analysis cited in company profiling suggests the shares may trade above their Fair Value, categorizing the stock among potentially overvalued equities.
On the corporate governance front, PTC Therapeutics recently expanded its board with the appointment of Jessica Chutter. Chutter joins the board with extensive experience from her time at Morgan Stanley, where she was engaged in capital-raising efforts and strategic transactions.
Analysts have adjusted and reiterated their views in recent weeks. Morgan Stanley lifted its price target on PTC Therapeutics to $92 while keeping an Overweight rating after the company pre-announced its fourth-quarter and full-year 2025 results. Cantor Fitzgerald reiterated an Overweight rating and set a price target of $124 following PTC’s fourth-quarter earnings report. Barclays initiated coverage with an Overweight rating and a $119 price target, highlighting the prospective value of the company’s investigational phenylketonuria treatment.
Meanwhile, PTC faced a regulatory setback when it withdrew a New Drug Application resubmission for Translarna after feedback from the U.S. Food and Drug Administration indicated the submitted data was unlikely to meet approval standards. That decision, paired with shifting analyst price targets and the insider sale, frames a period of mixed developments for the company.
Summary
Almstead sold 51,953 PTC Therapeutics shares under a 10b5-1 plan on April 1, 2026, realizing $3.59 million. The company has a market value of $5.61 billion and carries an "EXCELLENT" InvestingPro financial health score. Recent corporate and analyst developments include a board appointment, several analyst price-target updates, and the withdrawal of a Translarna NDA resubmission following FDA feedback.
Key points
- Insider sale: Almstead sold 51,953 shares under a pre-arranged 10b5-1 plan, generating $3.59 million.
- Analyst activity: Morgan Stanley, Cantor Fitzgerald, and Barclays have issued or updated Overweight ratings and various price targets ranging from $92 to $124.
- Regulatory update: PTC withdrew a Translarna NDA resubmission after FDA feedback suggested the data was unlikely to meet approval standards.
Risks and uncertainties
- Regulatory risk - Clinical and approval outcomes for Translarna are uncertain after the FDA indicated the resubmitted data was unlikely to meet approval standards.
- Valuation risk - InvestingPro analysis flags the stock as potentially overvalued relative to its Fair Value amid a 45% one-year share-price gain.
- Market and analyst sentiment - Divergent analyst price targets and ratings, while generally Overweight, reflect differing views on the company’s prospects and valuation.